The main prevention measure proposed is the prescription of the lowest possible dose of<unk>  replacement therapy to individuals at risk. The minimization of the use of<unk>  agonists, and of short duration formulations of L-Dopa can also decrease risk of the syndrome.
Dopamine dysregulation syndrome
Hyperprolactinemic SAHA syndrome
Sheehan's syndrome
Autoimmune polyendocrine syndrome
Hypothalamic disease
Dopamine transporter deficiency syndrome
Gerstmann syndrome
Hypopituitarism